These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900 [TBL] [Abstract][Full Text] [Related]
24. Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Shuai T; Yan P; Xiong H; Huang Q; Zhu L; Yang K; Liu J Biomed Res Int; 2019; 2019():6927456. PubMed ID: 31886242 [TBL] [Abstract][Full Text] [Related]
25. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Persson M; Engström G; Björkbacka H; Hedblad B Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508 [TBL] [Abstract][Full Text] [Related]
29. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes. Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985 [No Abstract] [Full Text] [Related]
30. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344 [TBL] [Abstract][Full Text] [Related]
31. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis. Wu W; Cui Y; Hu J; Liao R; Li S; Mo L; Xu L; Chen Y; Lian Z; Tian X; Li Z; Li R; Zhang L; Liang H; Ma J; Lin T; Feng Z; Dong W; Ke G; Ge P; Ye Z; Wang W; Zhang B; Shi W; Liang X; Liu S Kidney Blood Press Res; 2018; 43(3):664-672. PubMed ID: 29734173 [TBL] [Abstract][Full Text] [Related]
32. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Meijers B; Poesen R; Claes K; Dietrich R; Bammens B; Sprangers B; Naesens M; Storr M; Kuypers D; Evenepoel P Kidney Int; 2015 Jan; 87(1):210-6. PubMed ID: 24897037 [TBL] [Abstract][Full Text] [Related]
33. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine. Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136 [TBL] [Abstract][Full Text] [Related]
34. Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema. Hilty MP; Zügel S; Schoeb M; Auinger K; Dehnert C; Maggiorini M Mediators Inflamm; 2016; 2016():1942460. PubMed ID: 27378823 [TBL] [Abstract][Full Text] [Related]
35. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Gumus A; Altintas N; Cinarka H; Kirbas A; Hazıroglu M; Karatas M; Sahin U Int J Chron Obstruct Pulmon Dis; 2015; 10():357-65. PubMed ID: 25709430 [TBL] [Abstract][Full Text] [Related]
36. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis. Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165 [TBL] [Abstract][Full Text] [Related]
37. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Haupt TH; Petersen J; Ellekilde G; Klausen HH; Thorball CW; Eugen-Olsen J; Andersen O Crit Care; 2012 Jul; 16(4):R130. PubMed ID: 22824423 [TBL] [Abstract][Full Text] [Related]
38. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F Crit Care; 2011; 15(1):R63. PubMed ID: 21324198 [TBL] [Abstract][Full Text] [Related]
39. SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis. Hodges GW; Bang CN; Eugen-Olsen J; Olsen MH; Boman K; Ray S; Gohlke-Bärwolf C; Kesäniemi YA; Jeppesen JL; Wachtell K Can J Cardiol; 2016 Dec; 32(12):1462-1469. PubMed ID: 27499378 [TBL] [Abstract][Full Text] [Related]
40. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study. Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J; Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]